These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 28847181)

  • 21. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
    Pagonabarraga J; Rodríguez-Oroz MC
    Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of istradefylline in the Parkinson's disease armamentarium.
    Müller T
    Expert Opin Pharmacother; 2023 May; 24(7):863-871. PubMed ID: 37029952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levodopa in Parkinson's disease: from the past to the future.
    Pezzoli G; Zini M
    Expert Opin Pharmacother; 2010 Mar; 11(4):627-35. PubMed ID: 20163273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease.
    Wright BA; Waters CH
    Expert Rev Neurother; 2013 Jun; 13(6):719-29. PubMed ID: 23739008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of current and novel levodopa formulations for the treatment of Parkinson's disease.
    Jimenez-Shahed J
    Ther Deliv; 2016; 7(3):179-91. PubMed ID: 26893250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):693-699. PubMed ID: 28537214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New treatments for the motor symptoms of Parkinson's disease.
    Vijverman AC; Fox SH
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does Delaying Levodopa Prevent Motor Complications in Parkinson's Disease? A Meta-Analysis.
    Ramanzini LG; Frare JM; Camargo LFM; Silveira JOF; Jankovic J
    Mov Disord Clin Pract; 2024 Oct; 11(10):1195-1202. PubMed ID: 39189097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levodopa in the treatment of Parkinson's disease.
    Schapira AH; Emre M; Jenner P; Poewe W
    Eur J Neurol; 2009 Sep; 16(9):982-9. PubMed ID: 19538218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relevance of motor complications in Parkinson's disease.
    Adler CH
    Neurology; 2002 Feb; 58(4 Suppl 1):S51-6. PubMed ID: 11909985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.
    Gottwald MD
    Pharmacotherapy; 1999 Nov; 19(11 Pt 2):162S-8S. PubMed ID: 10555944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease.
    You H; Mariani LL; Mangone G; Le Febvre de Nailly D; Charbonnier-Beaupel F; Corvol JC
    Cell Tissue Res; 2018 Jul; 373(1):111-135. PubMed ID: 29516217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic strategies to prevent motor complications in Parkinson's disease.
    Kieburtz K
    J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
    Castro A; Valldeoriola F; Linazasoro G; Rodriguez-Oroz MC; Stochi F; Marin C; Rodriguez M; Vaamonde J; Jenner P; Alvarez L; Pavon N; Macias R; Luquin MR; Hernandez B; Grandas F; Gimenez-Roldan S; Tolosa E; Obeso JA
    Neurologia; 2005 May; 20(4):180-8. PubMed ID: 15891947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Off spells and dyskinesias: pharmacologic management of motor complications.
    Khan TS
    Cleve Clin J Med; 2012 Jul; 79 Suppl 2():S8-13. PubMed ID: 22761271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Medical treatment of Parkinson's disease].
    Waldvogel D
    Ther Umsch; 2007 Jan; 64(1):15-20. PubMed ID: 17221820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New and emerging medical therapies in Parkinson's disease.
    Lotia M; Jankovic J
    Expert Opin Pharmacother; 2016; 17(7):895-909. PubMed ID: 26830844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Motor symptoms in Parkinson disease].
    Larsen JP; Beiske AG; Bekkelund SI; Dietrichs E; Tysnes OB; Vilming ST; Aasly JO
    Tidsskr Nor Laegeforen; 2008 Sep; 128(18):2068-71. PubMed ID: 18846123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.